Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | The importance of TP53 & IGHV testing before treatment initiation in CLL

Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, discusses the importance of testing for IGHV and TP53 mutational status before treatment initiation in patients with chronic lymphocytic leukemia (CLL), commenting on their implications on treatment decisions. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.